Bristol-Myers Squibb Company (BMY)
NYSE: BMY · Real-Time Price · USD
44.23
+0.92 (2.12%)
At close: Aug 1, 2025, 4:00 PM
44.34
+0.11 (0.25%)
After-hours: Aug 1, 2025, 7:58 PM EDT
BMY Revenue
Bristol-Myers Squibb Company had revenue of $12.27B in the quarter ending June 30, 2025, with 0.56% growth. This brings the company's revenue in the last twelve months to $47.70B, up 2.57% year-over-year. In the year 2024, Bristol-Myers Squibb Company had annual revenue of $48.30B with 7.32% growth.
Revenue (ttm)
$47.70B
Revenue Growth
+2.57%
P/S Ratio
1.88
Revenue / Employee
$1,398,944
Employees
34,100
Market Cap
90.03B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 48.30B | 3.29B | 7.32% |
Dec 31, 2023 | 45.01B | -1.15B | -2.50% |
Dec 31, 2022 | 46.16B | -226.00M | -0.49% |
Dec 31, 2021 | 46.39B | 3.87B | 9.09% |
Dec 31, 2020 | 42.52B | 16.37B | 62.62% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
BMY News
- 13 hours ago - Bristol-Myers Squibb: No Respect For Blowout Earnings - Buy The Richer Dividend Yields - Seeking Alpha
- 13 hours ago - Bristol-Myers Q2 Earnings Review: Solid Quarter, But Incoming CMO Must Fix Pipeline - Seeking Alpha
- 13 hours ago - Bristol-Myers Squibb: Growth Is Taking Its Own Time (Rating Downgrade) - Seeking Alpha
- 15 hours ago - Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges - WSJ
- 18 hours ago - Bristol Myers: Dividend Growth, Raised Guidance, And A Double Beat - Seeking Alpha
- 1 day ago - Bristol-Myers Squibb Company (BMY) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says - Forbes
- 1 day ago - Trump pressures 17 pharma CEOs to cut US drug prices - Reuters